Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04464070 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pathways of Eicosanoid Metabolism

StatusEnrolling by Invitation
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Jul 31, 2026 to Jul 30, 2027
    • Study completion date: Aug 31, 2026 to Aug 31, 2027
    v13
  2. Primary completion date: May 31, 2025 to Jul 31, 2026
    • Study completion date: Aug 4, 2025 to Aug 31, 2026
    v12
  3. Primary completion date: May 31, 2023 to May 31, 2025
    • Study completion date: Aug 4, 2024 to Aug 4, 2025
    v11
  4. Primary completion date changed from estimate of Jul 31, 2024 to May 31, 2023v10
  5. Primary completion date: Jul 2023 to Jul 31, 2024
    • Study completion date: Jul 2023 to Aug 4, 2024
    v9
Show 7 earlier versionsHide 7 earlier versions
  1. Start date: Jan 14, 2021 to Aug 15, 2020v8
  2. Primary and study completion dates: Jul 2022 to Jul 2023v7
  3. Re-verified, no change to tracked fieldsv6
  4. Start date changed from estimate of Dec 2020 to Jan 14, 2021v5
  5. Start date: Oct 2020 to Dec 2020v4
  6. Start date: Aug 2020 to Oct 2020v3
  7. Start date: Jul 2020 to Aug 2020v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Prostaglandins are important signaling compounds formed from arachidonic acid. The enzymes that form prostaglandins, cyclooxygenase-1 and -2 are the targets of non-steroidal anti-inflammatory drugs (NSAIDs). Because prostaglandins are very unstable in the body, they can not be measured directly. Instead, their metabolites are isolated from urine or blood and quantified as markers of formation of the parent, active compounds. The investigators are testing the hypothesis that there is a previously unrecognized metabolic pathway between two prostaglandins. The investigators hypothesize that prostaglandin D2 (PGD2), in addition to its known metabolism to PGD-M, is also metabolized to 11-dehydro-thromboxane B2 (11-dehydro-TxB2).
Trial Details
NCT Number NCT04464070
Lead Sponsor Vanderbilt University
Collaborators: Vanderbilt University Medical Center
Conditions
(from sponsor)		 Metabolism of Prostaglandin D2
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov